MCID: DBT040
MIFTS: 42

Diabetes Mellitus, Insulin-Dependent, 2

Categories: Genetic diseases, Metabolic diseases, Rare diseases, Endocrine diseases

Aliases & Classifications for Diabetes Mellitus, Insulin-Dependent, 2

MalaCards integrated aliases for Diabetes Mellitus, Insulin-Dependent, 2:

Name: Diabetes Mellitus, Insulin-Dependent, 2 54 71 29 13 69
Type 1 Diabetes Mellitus 2 12 14
Iddm2 12 71
Insulin-Dependent Diabetes Mellitus 2 12

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant form (? 11q)


HPO:

32
diabetes mellitus, insulin-dependent, 2:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 125852
Disease Ontology 12 DOID:0110741
ICD10 33 E10
MedGen 40 C1852092
MeSH 42 D003922
SNOMED-CT via HPO 65 263681008 46635009

Summaries for Diabetes Mellitus, Insulin-Dependent, 2

UniProtKB/Swiss-Prot : 71 Diabetes mellitus, insulin-dependent, 2: A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

MalaCards based summary : Diabetes Mellitus, Insulin-Dependent, 2, also known as type 1 diabetes mellitus 2, is related to breast fibroadenoma and algoneurodystrophy, and has symptoms including type i diabetes mellitus An important gene associated with Diabetes Mellitus, Insulin-Dependent, 2 is INS (Insulin), and among its related pathways/superpathways are Type II diabetes mellitus and NF-kappaB Signaling. The drugs Pancrelipase and Insulin Aspart have been mentioned in the context of this disorder. Affiliated tissues include pancreas, kidney and testes.

Disease Ontology : 12 A type 1 diabetes mellitus that has material basis in autosomal dominant inheritance of mutation of the INS gene on chromosome 11p15.5.

Description from OMIM: 125852

Related Diseases for Diabetes Mellitus, Insulin-Dependent, 2

Diseases in the Diabetes Mellitus, Insulin-Dependent family:

Diabetes Mellitus, Insulin-Dependent, 19 Diabetes Mellitus, Insulin-Dependent, 7
Diabetes Mellitus, Insulin-Dependent, 12 Diabetes Mellitus, Insulin-Dependent, 13
Diabetes Mellitus, Insulin-Dependent, 22 Diabetes Mellitus, Insulin-Dependent, 23
Diabetes Mellitus, Insulin-Dependent, 18 Diabetes Mellitus, Insulin-Dependent, 15
Diabetes Mellitus, Insulin-Dependent, 21 Diabetes Mellitus, Insulin-Dependent, 5
Diabetes Mellitus, Insulin-Dependent, 8 Diabetes Mellitus, Insulin-Dependent, 24
Diabetes Mellitus, Insulin-Dependent, 17 Diabetes Mellitus, Insulin-Dependent, 2
Diabetes Mellitus, Insulin-Dependent, 4 Diabetes Mellitus, Insulin-Dependent, 20
Diabetes Mellitus, Insulin-Dependent, 11 Diabetes Mellitus, Insulin-Dependent, 3
Diabetes Mellitus, Insulin-Dependent, 6

Diseases related to Diabetes Mellitus, Insulin-Dependent, 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 29)
id Related Disease Score Top Affiliating Genes
1 breast fibroadenoma 10.4 IGF2 INS
2 algoneurodystrophy 10.3 IGF2 INS
3 fetal parvovirus syndrome 10.3 IGF2 INS
4 limb-mammary syndrome 10.3 IGF2 INS
5 kartagener syndrome 10.3 IGF2 INS
6 pericardial tuberculosis 10.3 IGF2 INS
7 neurogenic arthropathy 10.2 IGF2 INS
8 chondroma 10.2 IGF2 INS
9 diabetic cataract 10.1 IGF2 INS
10 multiple endocrine neoplasia 1 10.1 FGF3 GIMAP5
11 lung cancer susceptibility 2 10.0 IGF2 INS
12 breast cancer 10.0 CTLA4 INS
13 biliary cirrhosis, primary, 4 10.0 CTLA4 INS
14 nephrolithiasis/osteoporosis, hypophosphatemic, 1 10.0 IGF2 INS INS-IGF2
15 hypertrichosis 10.0 INS TNFRSF25
16 combined cellular and humoral immune defects with granulomas 9.9 CTLA4 INS
17 anterior segment dysgenesis 1, multiple subtypes 9.8 CTLA4 TNFRSF25
18 hyperglycemia 9.8
19 lymphopenia 9.8
20 cd3zeta deficiency 9.7 CTLA4 TNFRSF25
21 specific developmental disorder 9.7 CTLA4 TNFRSF25
22 lymphoma 9.6 CTLA4 TNFRSF25
23 neuropathy, hereditary sensory and autonomic, type ic 9.5 CTLA4 INS TNFRSF25
24 lacrimal system cancer 9.4 CTLA4 TNFRSF25
25 celiac disease 3 9.4 CTLA4 FGF3 INS
26 skin meningioma 9.4 CTLA4 INS
27 hepatic adenoma, somatic 9.0 CTLA4 IGF2 INS TNFRSF25
28 congenital heart defects, nonsyndromic, 2 8.9 CTLA4 FGF3 INS TNFRSF25
29 hyperphosphatasia with mental retardation syndrome 3 7.5 CTLA4 FGF3 GIMAP5 IGF2 INS INS-IGF2

Graphical network of the top 20 diseases related to Diabetes Mellitus, Insulin-Dependent, 2:



Diseases related to Diabetes Mellitus, Insulin-Dependent, 2

Symptoms & Phenotypes for Diabetes Mellitus, Insulin-Dependent, 2

Symptoms via clinical synopsis from OMIM:

54

Endo:
insulin-dependent diabetes mellitus


Clinical features from OMIM:

125852

Human phenotypes related to Diabetes Mellitus, Insulin-Dependent, 2:

32
id Description HPO Frequency HPO Source Accession
1 type i diabetes mellitus 32 HP:0100651

Drugs & Therapeutics for Diabetes Mellitus, Insulin-Dependent, 2

Drugs for Diabetes Mellitus, Insulin-Dependent, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 497)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53608-75-6
2
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1 116094-23-6 16132418
3
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1 133107-64-9
4
Insulin-glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1 207748-29-6
5
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
6
Diazoxide Approved Phase 4 364-98-7 3019
7
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1 169148-63-4 5311023
8
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1 160337-95-1
9
rituximab Approved Phase 4,Phase 1,Phase 2 174722-31-7 10201696
10
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
11
Metformin Approved Phase 4,Phase 3,Early Phase 1 657-24-9 14219 4091
12
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1 204656-20-2 44147092
13
Vildagliptin Approved, Investigational Phase 4,Phase 2 274901-16-5 6918537
14
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 141758-74-9 15991534
15
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
16
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
17
Norepinephrine Approved Phase 4 51-41-2 439260
18
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
19
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
20
Adenosine Approved, Investigational Phase 4 58-61-7 60961
21
Regadenoson Approved Phase 4 313348-27-5 219024
22
Ethanol Approved Phase 4,Phase 2,Early Phase 1 64-17-5 702
23
Gliclazide Approved Phase 4 21187-98-4 3475
24
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
25
Allopurinol Approved Phase 4 315-30-0 2094
26
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2 67-97-0 6221 10883523 5280795
27
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 50-14-6 5280793
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 1406-16-2
29
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 11103-57-4, 68-26-8 445354
30
Uric Acid Experimental, Investigational Phase 4 69-93-2 1175
31 gastric inhibitory polypeptide Phase 4,Phase 1,Phase 2
32 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 glucagon Phase 4,Phase 2,Phase 3,Phase 1
34 Glucagon-Like Peptide 1 Phase 4,Phase 2,Phase 3,Phase 1
35 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37 Incretins Phase 4,Phase 3,Phase 2,Phase 1
38 insulin Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Insulin, Globin Zinc Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
40 pancreatin Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Insulin degludec, insulin aspart drug combination Phase 4,Phase 3,Phase 2,Phase 1
42 Insulin, Long-Acting Phase 4,Phase 3,Phase 2,Phase 1
43 Insulin, Short-Acting Phase 4,Phase 3,Phase 1,Phase 2
44 Antihypertensive Agents Phase 4,Phase 3,Phase 2
45 Vasodilator Agents Phase 4,Phase 1,Phase 2
46 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
48 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
50 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1214)

id Name Status NCT ID Phase Drugs
1 Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Unknown status NCT01800734 Phase 4
2 CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) Unknown status NCT01848990 Phase 4 Commercial Hylenex® recombinant (hyaluronidase human injection);Precommercial Hylenex recombinant (hyaluronidase human injection);Insulin lispro;Insulin aspart;Insulin glulisine
3 Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 DM Unknown status NCT01338922 Phase 4
4 Dapagliflozin in Type 1 Diabetes Unknown status NCT02211742 Phase 4 Dapagliflozin
5 Use of Diazoxide in Acute Hypoglycaemia Unknown status NCT01488136 Phase 4 Diazoxide;Placebo
6 Comparing Long-acting Insulins During Exercise in Type 1 Diabetes Unknown status NCT01440439 Phase 4 Insulin glargine;Insulin detemir
7 Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes Unknown status NCT02232971 Phase 4 Glucagon
8 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Unknown status NCT01280682 Phase 4 rituximab
9 A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria Unknown status NCT00843388 Phase 4 Spironolacton (hexalacton(R));placebo tablet
10 Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children Completed NCT00069615 Phase 4
11 Continuous Glucose Monitors for Children With Diabetes Mellitus Completed NCT00069537 Phase 4
12 Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer Completed NCT00069628 Phase 4
13 Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase Completed NCT01526733 Phase 4 Sham Injection;Recombinant human hyaluronidase PH20;Insulin aspart;Insulin lispro
14 A Study for Patients With Diabetes Mellitus (IOPA) Completed NCT00420095 Phase 4 Human insulin 30/70;Insulin lispro low mix
15 Rosiglitazone and Insulin in T1DM Adolescents Completed NCT00372086 Phase 4 Rosiglitazone
16 Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet Completed NCT00118937 Phase 4 Metformin;Placebo.;Placebo.
17 Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes Completed NCT00660998 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
18 Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes Completed NCT00593255 Phase 4 soluble human insulin;insulin aspart;insulin NPH
19 Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes Completed NCT01390480 Phase 4 Cholecalciferol
20 Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial Completed NCT00542620 Phase 4 insulin detemir;insulin aspart;insulin detemir;insulin aspart
21 Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness Completed NCT00530023 Phase 4
22 Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes Completed NCT01467141 Phase 4 insulin aspart;human insulin;isophane human insulin
23 A Study on the Effect of 2 Pen Devices on HbA1c Completed NCT00985712 Phase 4 Insulin Lispro;Huminsulin Regular
24 Influence of Diabetes on Tramadol Pharmacokinetics Completed NCT02246712 Phase 4 Single oral dose of 100 mg racemic tramadol
25 Comparing the Metabolic Control of Once to Twice-daily Insulin Detemir Injections Completed NCT00542399 Phase 4 Levemir (insulin detemir);Levemir twice a day
26 Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Completed NCT00665093 Phase 4 biphasic insulin aspart 30;insulin detemir
27 Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment Completed NCT01099618 Phase 4 metformin;placebo;Sitagliptin
28 NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes Completed NCT00095446 Phase 4 insulin aspart
29 Effects of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes Completed NCT01397513 Phase 4 Aspirin
30 Comparison of Glycemic Control Achieved With 2 Different Needles Completed NCT00572052 Phase 4
31 Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus Completed NCT00607087 Phase 4 Insulin glulisine;Insulin lispro;Insulin aspart
32 Treatment Effects of Atorvastatin on Hemostasis and Skin Microcirculation in Patients With Type 1 Diabetes Completed NCT01497912 Phase 4 Atorvastatin;Placebo
33 Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes Completed NCT00315952 Phase 4 Exubera
34 Comparison of Insulins Aspart and Lispro in Insulin Pumps Completed NCT00461331 Phase 4 Insulin Aspart;Insulin Lispro
35 Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D) Completed NCT01019486 Phase 4 Regadenoson myocardial perfusion imaging;Regadenoson MRI myocardial blood flow
36 Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus Completed NCT00898534 Phase 4
37 Assessing Continuous Glucose Monitors in Healthy Children Completed NCT00069602 Phase 4
38 The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes Completed NCT02881060 Phase 4
39 The Effect of Supplementation With Two Different Doses of Vitamin D on Bone Mineral Density, Vitamin D Levels and Hand Grip Strength in Children With Diabetes Mellitus Type 1 Completed NCT01277913 Phase 4 Vitamin D3;Vitamin D3
40 Liraglutide in Type 1 Diabetes Completed NCT01612468 Phase 4 Liraglutide;Placebo
41 Sitagliptin Dose Determination Study Completed NCT01530178 Phase 4 Sitagliptin
42 The Effect of Metformin in Overweight Patients With Dysregulated Type 1 Diabetes Mellitus Completed NCT00145379 Phase 4 Tablet Metformin 500 mg;Placebo
43 Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Completed NCT00964574 Phase 4 INSULIN GLULISINE (HMR1964);INSULIN GLARGINE
44 Efficacy of Coordinated Insulin Boluses in Type 1 Diabetic Patients Completed NCT02229097 Phase 4 Normal bolus;Coordinated bolus
45 Pharmacokinetics of IAsp Following CSII in Patients With T1DM Completed NCT00497536 Phase 4 Insulin Aspart (IAsp);Insulin Aspart (IAsp).;Insulin Aspart (IAsp)
46 NovoLet® Acceptance Study Within the Hospital Practise in Indonesia Completed NCT01492205 Phase 4 insulin human
47 Surveillance Study of NovoRapid® for New Drug Re-examination Completed NCT01490112 Phase 4 insulin aspart
48 Improving Blood Pressure Management in Patients With Diabetes Completed NCT00374270 Phase 4
49 baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus Completed NCT01204593 Phase 4 INSULIN GLARGINE;INSULIN GLULISINE
50 Protection Against Pneumococcal Infection in Children With T1DM Completed NCT01939522 Phase 4

Search NIH Clinical Center for Diabetes Mellitus, Insulin-Dependent, 2

Genetic Tests for Diabetes Mellitus, Insulin-Dependent, 2

Genetic tests related to Diabetes Mellitus, Insulin-Dependent, 2:

id Genetic test Affiliating Genes
1 Diabetes Mellitus, Insulin-Dependent, 2 29

Anatomical Context for Diabetes Mellitus, Insulin-Dependent, 2

MalaCards organs/tissues related to Diabetes Mellitus, Insulin-Dependent, 2:

39
Pancreas, Kidney, Testes, Bone, Brain, Pancreatic Islet, T Cells

Publications for Diabetes Mellitus, Insulin-Dependent, 2

Variations for Diabetes Mellitus, Insulin-Dependent, 2

UniProtKB/Swiss-Prot genetic disease variations for Diabetes Mellitus, Insulin-Dependent, 2:

71
id Symbol AA change Variation ID SNP ID
1 INS p.Arg55Cys VAR_063732 rs121908261

ClinVar genetic disease variations for Diabetes Mellitus, Insulin-Dependent, 2:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 INS NM_000207.2(INS): c.163C> T (p.Arg55Cys) single nucleotide variant Pathogenic rs121908261 GRCh37 Chromosome 11, 2182039: 2182039
2 INS; INS-IGF2 NM_000207.2(INS): c.94G> A (p.Gly32Ser) single nucleotide variant Pathogenic rs80356664 GRCh37 Chromosome 11, 2182108: 2182108

Expression for Diabetes Mellitus, Insulin-Dependent, 2

Search GEO for disease gene expression data for Diabetes Mellitus, Insulin-Dependent, 2.

Pathways for Diabetes Mellitus, Insulin-Dependent, 2

Pathways related to Diabetes Mellitus, Insulin-Dependent, 2 according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.3 INS INS-IGF2
2 11.29 CTLA4 GIMAP5 TNFRSF25
3 11.05 FGF3 IGF2
4 10.93 CTLA4 TNFRSF25
5 10.68 IGF2 INS

GO Terms for Diabetes Mellitus, Insulin-Dependent, 2

Cellular components related to Diabetes Mellitus, Insulin-Dependent, 2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.02 FGF3 IGF2 INS INS-IGF2 TNFRSF25

Biological processes related to Diabetes Mellitus, Insulin-Dependent, 2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.65 FGF3 IGF2 INS
2 positive regulation of protein kinase B signaling GO:0051897 9.46 IGF2 INS
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.43 IGF2 INS
4 positive regulation of MAPK cascade GO:0043410 9.4 IGF2 INS
5 insulin receptor signaling pathway GO:0008286 9.37 IGF2 INS
6 glucose metabolic process GO:0006006 9.32 IGF2 INS
7 positive regulation of cell division GO:0051781 9.26 FGF3 IGF2
8 positive regulation of mitotic nuclear division GO:0045840 9.16 IGF2 INS
9 positive regulation of glycogen biosynthetic process GO:0045725 8.96 IGF2 INS
10 positive regulation of insulin receptor signaling pathway GO:0046628 8.62 IGF2 INS

Molecular functions related to Diabetes Mellitus, Insulin-Dependent, 2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.16 IGF2 INS
2 insulin-like growth factor receptor binding GO:0005159 8.96 IGF2 INS
3 hormone activity GO:0005179 8.8 IGF2 INS INS-IGF2

Sources for Diabetes Mellitus, Insulin-Dependent, 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....